Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis is a lung disease with limited therapeutic options that is characterized by pathological fibroblast activation and aberrant lung remodeling with scar formation. YAP (Yes-associated protein) is a transcriptional coactivator that mediates mechanical and biochemical signals controlling fibroblast activation. In this study, we developed a high-throughput small-molecule screen for YAP inhibitors in primary human lung fibroblasts. Multiple HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase inhibitors (statins) were found to inhibit YAP nuclear localization via induction of YAP phosphorylation, cytoplasmic retention, and degradation. We further show that the mevalonate pathway regulates YAP activation, and that simvastatin treatment reduces fibrosis markers in activated human lung fibroblasts and in the bleomycin mouse model of pulmonary fibrosis. Finally, we show that simvastatin modulates YAP in vivo in mouse lung fibroblasts. Our results highlight the potential of small-molecule screens for YAP inhibitors and provide a mechanism for the antifibrotic activity of statins in idiopathic pulmonary fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Statins, including simvastatin, have also shown antifibrotic potential in preclinical studies by promoting YAP cytoplasmic retention and inactivation, offering opportunities for drug repurposing (144, 145).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“Plates were monitored for cell density, percentage of nuclear YAP(1) cells in control wells, and z-scores (26), and rescreened if deemed necessary.”
BackgroundRole of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092 · cited 6×
“Accordingly, statins induced a marked increase in the phosphorylation of serine 397 (pS397) (Figures 3A and 3B), which marks YAP for proteasomal degradation (28).”
BackgroundInfluentialTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
The Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,802 · cited 2×
“Statin treatment was associated with decreased cell numbers (Figure E3A), probably due to inhibition of proproliferative YAP/TAZ signaling (27).”
BackgroundMethodSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Mechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667 · cited 2×
“YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) are transcriptional coactivators that when active translocate to the nucleus and induce the expression of a wide range of genes, controlling cell proliferation, survival, and migration (10).”
BackgroundAragona, M., Panciera, T., Manfrin, A., Giulitti, S., Michielin, F., Elvassore, N., Dupont, S., & Piccolo, S. (2013) · Cell · doi:10.1016/j.cell.2013.07.042 · Cited by 1,651 · cited 8×
“In our investigation of the antifibrotic potential of statins, we also found that statins Santos, Pantano, Pronzati, et al.: IPF Drug Screen: Statins Inhibit YAP in Lung Fibroblasts 489 prevented HLF activation by TGF-b, reducing the expression of profibrotic genes (CTGF, CYR61, ACTA2, and COL1A1) and preventing actin…”
BackgroundInfluential
Research works printed but not linked: 1
- Santos DM, Pantano L, Pronzati G, Grasberger P, Probst CK, Black KE, et al. A high-throughput small molecule screen for YAP inhibitors identifies statins as inhibitors of fibroblast activation and pulmonary fibrosis [abstract] Am J Respir Crit Care Med. 2019;199:A5878. [Google Scholar]
Cited by
The extracellular matrix and mechanotransduction in pulmonary fibrosis
Deng, Z., Fear, M. W., Suk Choi, Y., Wood, F. M., Allahham, A., Mutsaers, S. E., & Prêle, C. M. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105802 · Cited by 120
New Insights into Hippo/YAP Signaling in Fibrotic Diseases
Mia, M. M., & Singh, M. K. (2022) · Cells · doi:10.3390/cells11132065 · Cited by 116
“This study found that simvastatin modulates YAP localization in mouse lung fibroblasts in vivo and reduces established fibrosis in bleomycin-challenged mouse IPF (Table 1) [67].”
BackgroundInfluentialFibrosis: cross-organ biology and pathways to development of innovative drugs
Rieder, F., Nagy, L. E., Maher, T. M., Distler, J. H. W., Kramann, R., Hinz, B., & Prunotto, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01158-9 · Cited by 154
“Several statins recently emerged from high-throughput screens with small-molecule libraries as possible regulators of YAP signalling and drugs that target the mevalonate pathway in human lung fibroblasts 126 .”
YAP/TAZ: Molecular pathway and disease therapy
Wei, Y., Hui, V. L. Z., Chen, Y., Han, R., Han, X., & Guo, Y. (2023) · MedComm · doi:10.1002/mco2.340 · Cited by 122
Hippo signaling pathway and respiratory diseases
Tang, W., Li, M., Yangzhong, X., Zhang, X., Zu, A., Hou, Y., Li, L., & Sun, S. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01020-6 · Cited by 90
“Lung fibroblasts are the main effector cells of IPF, and the YAP mediates the proliferation, migration, and collagen deposition of lung fibroblasts induced by mechanical signals [100, 101].”
Background
Metadata
- Authors
- Santos, D. M., Pantano, L., Pronzati, G., Grasberger, P., Probst, C. K., Black, K. E., Spinney, J. J., Hariri, L. P., Nichols, R., Lin, Y., Bieler, M., Seither, P., Nicklin, P., Wyatt, D., Tager, A. M., & Medoff, B. D.
- Affiliations
- Division of Pulmonary and Critical Care Medicine, and
- Harvard University (US)
- Computational Chemistry
- Business Development and Licensing
- Research Beyond Borders, and
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Medoff, Benjamin D.
- ORCID
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-01
- Volume
- 62
- Issue
- 4
- Pages
- 479-492
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- PMC
- PMC7110981
- OpenAlex
- W3003235367
- Cited by
- 72
- References
- 76
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 15 · 2023: 15 · 2022: 12 · 2021: 7 · 2020: 3
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL133153, K08HL133603)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- YAP, YAP inhibitor, statins, simvastatin, idiopathic pulmonary fibrosis, lung fibroblasts, fibroblast activation, mevalonate pathway, YAP phosphorylation, antifibrotic agents, bleomycin-induced fibrosis
- MeSH terms
- YAP-Signaling Proteins, Acyl Coenzyme A, Animals, Bleomycin, Cell Nucleus, Cytoplasm, Fibroblasts, Humans, Mevalonic Acid, Phosphoproteins, Pulmonary Fibrosis, Signal Transduction, Biomarkers, Cell Cycle Proteins, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Adaptor Proteins, Signal Transducing, Mice, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.